Companhia Brasileira de Distribuicao (CBD)
(Real Time Quote from BATS)
$0.45 USD
+0.01 (1.12%)
Updated Apr 18, 2024 08:44 PM ET
3-Hold of 5 3
A Value A Growth A Momentum A VGM
Price, Consensus and EPS Surprise
CBD 0.45 +0.01(1.12%)
Will CBD be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for CBD based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CBD
Companhia Brasileira (CBD) Up More Than 40% YTD: Here's Why
Zacks Industry Outlook Highlights Walmart, The Kroger and Companhia Brasileira de Distribuicao
CBD: What are Zacks experts saying now?
Zacks Private Portfolio Services
3 Supermarket Stocks Worth Watching on Solid Industry Trends
Zacks Industry Outlook Highlights Walmart, Kroger and Companhia Brasileira de Distribuicao
3 Supermarket Stocks to Watch on Impressive Industry Trends
Other News for CBD
This CBD And Hemp Co. Reports 82% YoY Increase In 2023 Revenue, Thanks To Its 'International Appeal'
Pakistan Launches Regulatory Body For Cannabis Trade To Fuel Economic Growth
Functional Cannabis With Pharma Nanotech? How KanhaFX Boosts Cannabinoid Delivery And Market Share
Analyst Reacts To FDA Commish Comments: Medical And Recreational Cannabis Could Have Separate Regulations
EXCLUSIVE: AI In Dispensaries? New Tech Aims To Personalize Cannabis Shopping Experience